Jallal
MedImmune
AstraZeneca
Belgium
Biography
Bahija Jallal, Executive Vice-President of MedImmune, is responsible for biologics research, development and clinical activities.Bahija joined MedImmune as Vice-President, Translational Sciences in 2006. She has guided the MedImmune R&D organisation through unprecedented expansion of its pipeline from 40 drugs to more than 120. Biologics now makes up 50% of AstraZeneca’s pipeline. Bahija has authored more than 70 peer-reviewed publications and holds more than 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science, the Pharmacogenomics Working Group and is a member of the Board of Directors of the Association of Women in Science.
Research Interest
MedImmune
